- Conditions
- Delirium in Old Age
- Interventions
- Suvorexant 20 mg, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Insomnia
- Interventions
- Suvorexant, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 11
- States / cities
- New Haven, Connecticut • Savannah, Georgia • Baltimore, Maryland + 8 more
- Conditions
- Chronic Post-traumatic Headache
- Interventions
- Rizatriptan, Placebo
- Drug
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years to 49 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Retinal Detachment
- Interventions
- denufosol tetrasodium (INS37217) Intravitreal Injection
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 29 more
- Conditions
- Melanoma
- Interventions
- Pembrolizumab, Vibostolimab, Gebasaxturev, MK-4830, Favezelimab + Pembrolizumab, ATRA
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
- Conditions
- Heart Failure
- Interventions
- Zepatier
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Solid Tumors
- Interventions
- E7080, Comparator Drug, Comparator Drug: Sorafenib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- Torrance, California • Chicago, Illinois • Detroit, Michigan
- Conditions
- Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
- Interventions
- Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy
- Radiation · Other · Biological
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Clostridium Difficile Infection (CDI)
- Interventions
- Fidaxomicin
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diabetes, Atherosclerosis
- Interventions
- sitagliptin, Placebo
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Ovarian Cancer
- Interventions
- Pembrolizumab, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy
- Interventions
- Treatment with ARQ 197
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Colorectal Neoplasms
- Interventions
- pembrolizumab, lenvatinib, regorafenib, TAS-102 (trifluridine and tipiracil)
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 12
- States / cities
- Monterey, California • Marietta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Malignant Neoplasm of Breast
- Interventions
- Imprime PGG, Pembrolizumab
- Biological
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Denver, Colorado • Miami, Florida + 12 more
- Conditions
- Insomnia, Bipolar Disorder
- Interventions
- Suvorexant, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Advanced Solid Tumors
- Interventions
- ASP1951, pembrolizumab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Sacramento, California • Gainesville, Florida + 15 more
- Conditions
- Human Papillomavirus
- Interventions
- Not listed
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,036 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Leukemia, Myelodysplastic Syndrome
- Interventions
- bortezomib, vorinostat
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Metastatic Solid Tumors, Advanced Solid Tumors
- Interventions
- MK-0472, Pembrolizumab, MK-1084
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Hackensack, New Jersey + 1 more
- Conditions
- Cardiovascular Diseases, Hepatitis C, Hiv
- Interventions
- Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
- Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Posttransplant Diabetes Mellitus
- Interventions
- Sitagliptin, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Type 2 Diabetes, African American, Cholesterol, Lipoprotein, Apolipoprotein
- Interventions
- Not listed
- Lead sponsor
- Mercer University
- Other
- Eligibility
- 18 Years to 79 Years · Male only
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Lung Cancer
- Interventions
- Erlotinib, AZD6244, MK-2206, Sorafenib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Houston, Texas
- Conditions
- Healthy
- Interventions
- V540D, GARDASIL®9
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Hollywood, Florida • Savannah, Georgia • Kansas City, Missouri + 1 more